TAXIS Pharmaceuticals Receives NIH SBIR Grant to Advance Development of Novel Antibiotic Class for Clostridioides difficile Infections

Positive

AI Analysis

Summary

TAXIS Pharmaceuticals received its third NIH SBIR grant in over two years to advance development of a novel narrow-spectrum antibiotic targeting hypervirulent Clostridioides difficile strains.

Outcome Details

NIH SBIR grant awarded

Importance:5/10

Sentiment:

0.60

NIH fundingSBIR grantantibiotic developmentC. difficilenarrow-spectrum therapy

Related Companies

$SPPI

Read the original article

Published by PR Newswire Biotech on August 17, 2026 12:29 PM

Read Original